|
Published online before print March 18, 2009, doi:10.1212/01.wnl.0b013e3181a1863c)
© 2009 American Academy of Neurology Risk factors associated with major cerebrovascular complications after intracranial stentingFrom Emory University (F.N., M.J.L., B.L.), Atlanta, GA; University of Pennsylvania Medical Center (S.E.K.), Philadelphia; Cedars-Sinai Medical Center (M.J.A.), Los Angeles, CA; Methodist Hospital (R.K.), Houston, TX; Medical College of Wisconsin/Froedtert Hospital (O.O.Z.), Milwaukee; University of Iowa (J.C.), Iowa City; Oregon Health and Science University (H.L., S.B.), Portland; Baylor College of Medicine (M.M.), Houston, TX; and Medical University of South Carolina (M.I.C.), Charleston. Address correspondence and reprint requests to Dr. Fadi Nahab, 1365 Clifton Road, NE, Building A, 3rd Floor, Atlanta, GA 30322 fnahab{at}emory.edu Background: There are limited data on the relationship between patient and site characteristics and clinical outcomes after intracranial stenting. Methods: We performed a multivariable analysis that correlated patient and site characteristics with the occurrence of the primary endpoint (any stroke or death within 30 days of stenting or stroke in the territory of the stented artery beyond 30 days) in 160 patients enrolled in this stenting registry. All patients presented with an ischemic stroke, TIA, or other cerebral ischemic event (e.g., vertebrobasilar insufficiency) in the territory of a suspected 50–99% stenosis of a major intracranial artery while on antithrombotic therapy.
Results: Cerebral angiography confirmed that 99% (158/160) of patients had a 50–99% stenosis. In multivariable analysis, the primary endpoint was associated with posterior circulation stenosis (vs anterior circulation) (hazard ratio [HR] 3.4, 95% confidence interval [CI] 1.2–9.3, p = 0.018), stenting at low enrollment sites (<10 patients each) (vs high enrollment site) (HR 2.8, 95% CI 1.1–7.6, p = 0.038), Conclusions: Major cerebrovascular complications after intracranial stenting may be associated with posterior circulation stenosis, low volume sites, stenting soon after a qualifying event, and stroke as the qualifying event. These factors will need to be monitored in future trials of intracranial stenting.
Abbreviations: CI = confidence interval; HR = hazard ratio.
e-Pub ahead of print on March 18, 2009, at www.neurology.org. Supported by NIH/NINDS grant R01 NS051688-01 to Dr. Marc Chimowitz. Disclosure: Drs. Zaidat, Alexander, Barnwell, Lutsep, Chaloupka, and Mawad consult for or have received an honorarium from Boston Scientific Inc., the manufacturers of the Wingspan stent. Medications and Medical Devices: clopidogrel (Plavix®, Bristol-Myers Squibb/Sanofi Pharmaceuticals, Bridgewater, NJ); Gateway® balloon angioplasty (Boston Scientific, Fremont, CA); Wingspan® intracranial stent (Boston Scientific, Fremont, CA). Presented in part at the annual meeting of the American Academy of Neurology, Chicago, IL, April 17, 2008; and the International Stroke Conference, New Orleans, LA, February 21, 2008. Received September 4, 2008. Accepted in final form January 13, 2009.
Related Article
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
10 days from qualifying event to stenting (vs 
10 days) (HR 2.7, 95% CI 1.0–7.8, p = 0.058), and stroke as a qualifying event (vs TIA/other) (HR 3.2, 95% CI 0.9–11.2, p = 0.064). There was no significant difference in the primary endpoint based on age, gender, race, or percent stenosis (50–69% vs 70–99%). 
